Background: There has been little emphasis in the past upon management of excessive secretions in patients with esophageal cancer. We used the drug glycopyrrolate for controlling secretions in patients with esophageal cancer.
Introduction
Esophageal cancer is an important problem in the United States. It results in more deaths (over 10,000 annually) than rectal cancer [1] . Unfortunately, most patients with esophageal cancer present with advanced incurable disease. Prognosis is extremely poor regardless of therapy used; overall, only 3% of the patients survive for five years. Often, only symptomatic palliation is possible. Although dysphagia and weight loss are the most common symptoms, one of the most distressing symptoms is excessive secretions. This problem has not been addressed to a great extent in the past.
Glycopyrrolate (Robinul, Richmond, VA, USA) is a quaternary ammonium compound in contrast to conventional anticholinergic compounds like atropine and scopolamine which are tertiary amines [2] . Strongly ionized agents such as quaternary amines are unable to enter the central nervous system (CNS) from the circulation thus avoiding CNS toxicity [3] . This is a long acting drug with peripheral antimuscarinic effects. Glycopyrrolate is commonly administered through oral, intramuscular or intravenous routes.
It is used for the treatment of various gastrointestinal disorders and in anesthesia as an antisialogogue and to prolong the effectiveness of some anticholinesterases such as physostigmine and neostigmine against neuromuscular blockade [4] . We used glycopyrrolate to manage increased secretions in esophageal cancer patients.
Patients and methods
The records of 45 consecutive patients with esophageal cancer admitted to Veterans Affairs Medical Center, Washington, DC between January 1991 and September 1995 were reviewed. Seven of these patients were given glycopyrrolate to control their secretions. Six of these seven patients received combination chemotherapy and radiotherapy for their cancer. The other 38 patients were not given this drug as they did not have a major problem handling secretions The dose of the glycopyrrolate given was 0.2 mg every six hours. Six patients were given the i.v. preparation of glycopyrrolate through a gastrostomy tube while one was treated by nebulization. The volume of secretions was measured over 24 hours in a Baxter Suction Canister (Deerfield, IL, USA).
Results
All seven patients responded to treatment and showed a substantial decrease in secretions within 24-48 hours of receiving glycopyrrolate (Table 1 ). The average duration of treatment was 34 days which represented the average life span of these terminally ill patients. The most common side effect was asymptomatic transient mild sinus tachycardia with no dysrhythmias or changes in blood pressure seen in five of seven patients. One patient with borderline prostatic hypertrophy developed urinary retention requiring temporary bladder catherization. None of the patients experienced CNS side effects. One patient had constipation but he was also receiving 120 mg morphine daily and this symptom was relieved by laxatives. Therapy did not have to be interrupted because of toxicity. We were able to use the drug for extended periods of time without significant problems. Patients complaining of excessive secretions improved considerably and they felt much better within 24-48 hours of administration. Their quality of life was improved.
Discussion
With rare exceptions, carcinoma of esophagus is at diagnosis a systemic disease. Palliation is the primary goal for patients with advanced esophageal cancer. Although the most common clinical symptom of esophageal cancer is progressive dysphagia, one of the most distressing symptom is increased secretions. This results from esophageal obstruction which causes difficulty in swallowing saliva leading to a tendency to aspirate. Tracheoesophageal fistula may develop as the disease progresses leading to severe suffering. Radiation therapy causes excessive secretions and can occasional result in the formation of tracheoesophageal fistula. Controlling these secretions becomes a major quality of life issue.
Glycopyrrolate is a synthetic quaternary ammonium compound with long acting anticholinergic properties. Franko et al. [5] found that glycopyrrolate possessed a high degree of sensitivity for peripheral anticholinergic sites relative to atropine. Glycopyrrolate (0.2 mg) has three times as much antisialogogue action as atropine (0.4 mg) [6] . It is slower in onset and produces less tachycardia than atropine or scopolamine which can be of benefit in patients with compromised cardiac reserve [2] . It has been shown that glycopyrrolate penetration through the blood-brain and placental barriers is extremely poor compared with atropine [7] .
Many studies have demonstrated that glycopyrrolate virtually lacks CNS side effects whereas atropine may cause CNS stimulation followed by depression [8] and delirium is also a common manifestation of advanced cancer [9] . The gastrointestinal absorption of quaternary amines like glycopyrrolate appears to be slow and erratic and drug dose may need to be titrated to the individual patient [10] . Even when administered in amounts above the recommended dose, there is little change in heart rate, blood pressure, bladder function, intraocular pressure or pupillary diameter [8] . This results from very inefficient absorption of the drug from lungs or gastrointestinal tract [8] . Adverse cardiovascular, central nervous system, dermatologic, gastrointestinal, genitourinary and ocular are usually less than 1% [8] probably due to erratic drug absorption. However, the low plasma levels are associated with a distinct and longstanding antisialogogue action with a maximum effect six hours after drug ingestion [8] . When administered intravenously, it was found to have a short elimination phase, so it has a short anti-secretory action of 2-3 hours [11] . We used glycopyrrolate injections through the gastrostomy tube. We found this beneficial in patients with odynophagia, mucositis and radiation esophagitis as these patients have difficulty taking medications orally. One must be cautious in the use of this medication, as it reduces the tone of smooth muscles in the urinary tract leading to decreased motility [12] . It should be used cautiously in patients with prostatic hypertrophy because it can precipitate urinary retention as happened in one of our patients. We conclude that glycopyrrolate administered via the gastrostomy tube is effective in alleviating symptoms of increased secretions without significant side effects.
